News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Discover Latest #Import News, Articles and Videos with Contenting
News: 1. Microsoft unveils new Windows 10 features to make remote work easier 2. Google launches new Chrome OS features to boost productivity 3. Apple announces new iOS 14 features to improve user experience Articles: 1. How to Use Windows 10 Features to Make Remote Work Easier 2. Why Chrome OS Is the Best Choice for Remote Productivity 3. The Benefits of Upgrading to iOS 14 for Improved User Experience Videos: 1. Windows 10 Tutorial: How to Use Remote Desktop 2. Chrome OS Productivity Tips and Tricks 3. iOS 14: What's New and How to Use It
Copper Holds Near 3-Month High on Tariff Risks - ForexTV
Copper futures remained above $5.10 per pound on Thursday, nearing a three-month peak as global supply constraints and uncertainties around tariffs spurred buying interest. Market participants are rerouting copper shipments to the U.S. in anticipation of potential import tariffs, resulting in significant inventory reductions at the London Metal Exchange and Shanghai Futures Exchange. There is mounting speculation about the implementation of a 10% tariff on U.S. copper imports, which is causing a wider price differential between Comex and LME copper contracts, currently standing at approximately $1,300 per ton. Analysts caution, however, that this recent price surge could quickly reverse if U.S. demand declines or if tariff announcements fall short of expectations. Simultaneously, copper prices are bolstered by strong demand prospects from China. Notably, a private survey revealed that Chinese manufacturing activity surprisingly rebounded to growth in June, indicating that the world's largest copper consumer might be benefiting from reduced trade tensions with the U.S.The material has been provided by InstaForex Company - www.instaforex.com
Vietnam Stocks Hit Over 3-Year High on US Trade Deal - ForexTV
Equity markets in Vietnam experienced a 6-point uplift, or a 0.4% increase, reaching 1,391 by midday on Thursday, marking their highest point since April 2022. This surge followed the announcement of a trade agreement between the United States and Vietnam by US President Donald Trump. The accord includes a revised US tariff on Vietnamese imports, reducing the duty from an anticipated 46% to a more favorable 20%, effective next week. This development has been positively received by traders, as the United States stands as Vietnam’s largest trading partner, with exports to the US constituting roughly 30% of Vietnam's GDP in the previous year. The market saw widespread gains, particularly in the consumer non-durable and health services sectors. Notable advances were recorded by Dai Thien Loc Corp, Phuong Nam Cultural, and Duc Long Gia, all appreciating by 7%. Additionally, Vietnam Container Shipping and Truong Thanh Furniture climbed 6.9% and 6.6%, respectively.The material has been provided by InstaForex Company - www.instaforex.com
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies - ForexTV
Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform OBT receives milestone payment associated with advance of drug candidate Oxford, UK and San Jose, California, 3 July 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies, today announced that Boehringer Ingelheim has selected a third drug candidate, which will now advance into IND-enabling studies under their ongoing collaboration. The target, OB33, was identified using OBT’s proprietary OGAP®-Verify discovery platform. As a result of this milestone, OBT will receive a payment from Boehringer. Immuno-oncological therapies have transformed the cancer treatment landscape. They are however only effective in a subset of patients, requiring the identification of novel immunotherapy targets. The collaboration with Oxford BioTherapeutics complements Boehringer Ingelheim’s development of next-generation potentially life-changing cancer immunotherapies with the identification of unique and specific cancer targets. Dr. Christian Rohlff, Chief Executive Officer, said: “We are pleased to see our partnership with Boehringer Ingelheim reach an important preclinical milestone. It reflects the strength of our collaboration and the scientific excellence of our OGAP discovery platform. This achievement reinforces our strategy of partnering with world-class organizations to translate breakthrough science into potential new cancer therapies. We look forward to the next phase of this highly successful partnership and to continuing to work together to develop innovative first-in-class treatments for patients with difficult to treat cancers.” OBT’s recently launched enhanced OGAP®-Verify discovery platform allows for enhanced sensitivity and target selection, addressing key challenges in the design of therapeutic antibodies and diagnostic tools. This has resulted in an increased overall success rate of these novel compounds transitioning into clinical development. Under the multi-year collaboration, OBT has identified targets using the OGAP®-Verify platform, while Boehringer is responsible for the development and commercialization of resulting product candidates. The OBT–Boehringer partnership began in 2013 and has expanded through subsequent agreements in 2020 and 2022 to include additional programs. The collaboration has yielded multiple development-stage assets, with two candidates currently in clinical trials, one compound now in IND enabling studies, and a fourth target recently optioned by Boehringer Ingelheim. *** About Oxford BioTherapeutics Oxford BioTherapeutics is a clinical stage oncology company discovering and developing first in class antibody-based therapies designed to fulfil major unmet patient needs in cancer therapy. These include Bispecific Antibodies and Antibody Drug Conjugate (ADC) therapeutics. OBT is dedicated to discovering and validating the next generation of ADC targets for safe and effective medicines. The OGAP®-Verify platform’s enhanced sensitivity, specificity, and reliability will significantly accelerate biopharma’s capabilities to identify and validate human targets with robust scientific support. Our commitment to leveraging OGAP capabilities underscores our dedication to advancing the forefront of cancer therapy development, with three programs originating from this technology now in clinical development in the US and Europe. OBT’s Immuno-oncology discovery process provides unique insights into the cancer-immune cell synapse and has identified several novel IO monoclonal and bispecific antibody candidates for cancer therapies. OBT's lead clinical program, OBT076, is currently in Phase I clinical trials in patients with advanced or refractory solid tumors, including gastric, bladder, ovarian and lung cancers, where CD205 is overexpressed. OBT’s pipeline and development capabilities have been validated through multiple strategic partnerships including with Roche, Boehringer Ingelheim, ImmunoGen (now part of Abbvie) and Zymeworks as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS) and Alere (Abbott). OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies. For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com and follow us on LinkedIn. Partnering:Dr Christian Rohlff, CEOPartnering@oxfordbiotherapeutics.com Media:MEDiSTRAVA Sylvie Berrebi, Sandi Greenwood, Erica HollingsworthE : OBT@medistrava.comT : +44 (0)203 928 6900
Bookkeeping vs. Accounting: What’s the Difference and Why It Matters - TechBullion
When people talk about money in a business, they usually discuss two things: bookkeeping and accounting. These words sound like they mean the same thing, but they don’t. They both are very important for keeping a business healthy with money, but they do different jobs. It’s good to know the difference. If you understand how […]